<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01192204</url>
  </required_header>
  <id_info>
    <org_study_id>2009C0086</org_study_id>
    <secondary_id>RC2CA148099</secondary_id>
    <nct_id>NCT01192204</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention</brief_title>
  <official_title>Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter placebo-controlled clinical trial to assess the effects of a topically
      applied gel on precancerous oral epithelial lesions. A total of 41 participants will be
      enrolled in this trial, and 22 of them will be enrolled at Ohio State. [The remaining 19
      participants will be enrolled at the University of North Carolina (9 participants) and the
      University of Louisville (8 participants)]. At all three institutions, half of the
      participants will randomly be assigned to the 10% FBR gel (0.5 gm four times daily for 3
      months), while half will enter the placebo control arm. All trial participants will have a
      pretreatment (including lesional and perilesional tissue) biopsy taken before and an
      excisional biopsy after 3 months of treatment. As pretreatment indices are compared to post
      treatment effects on each patient, patients serve as their own internal control. Pretreatment
      lesional biopsies are obtained to establish a pretreatment diagnosis and provide a
      pretreatment baseline for the experimental parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Forty one (41) patients with microscopically confirmed premalignant oral epithelial disease
      (epithelial dysplasia) will be enrolled in this trial at three clinical centers, i.e. the
      Ohio State University, University of North Carolina at Chapel Hill and University of
      Louisville. At all three institutions, half of the participants will randomly be assigned to
      the 10% FBR gel (0.5 gm four times daily for 3 months), while half will enter the placebo
      control arm.

      In accordance with the established standard of care, all participants need to have biopsies
      taken of their suspicious oral lesions to establish the diagnosis (non research). Trial
      participants will have three total biopsies. Pretreatment biopsies will entail: 1)
      perilesional tissue and single saliva sample for FBR metabolic profiling studies (tissue and
      saliva will be obtained 15 minutes after a single 0.5 gm application of 10% FBR gel for
      metabolic profiling. Gel application and nonlesional biopsy will be obtained before
      incisional biopsy of lesional tissue), and 2) a hemisection of lesional tissue to establish a
      diagnosis and provide a pretreatment baseline for the experimental parameters. While the
      pretreatment biopsy includes removal of both perilesional and lesional tissue, there will
      only be one surgical wound as the perilesional tissue is contiguous with the lesional tissue.
      A final excisional biopsy of the treatment site including any remaining residual lesional
      tissue (excision of oral dysplastic lesions is consistent with current standards of care)
      will be obtained after 3 months of treatment. The experimental design permits each patient to
      serve as their own internal control. Briefly, these following parameters will be monitored in
      all participants (comparisons made relative to patient-matched pretreatment to posttreatment
      biopsies): 1) light microscopic diagnoses, 2) clinical appearances and lesional sizes, 3)
      microarray gene expression analyses, 4) microvascular densities of superficial connective
      tissues, 5) LOH indices at loci associated with tumor suppressor genes, 6) intraepithelial
      levels of COX-2 and iNOS protein (image analysis quantified immunohistochemistry), 7)
      comparison of FBR metabolic profiles relative to extent of chemopreventive efficacy noted.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Light Microscopic Histologically Scored Diagnoses Pretreatment to Post Treatment</measure>
    <time_frame>Before and after the 3 month treatment.</time_frame>
    <description>A hemisection of lesional tissue will be conducted before the 3 month treatment to establish a diagnosis and provide a pretreatment baseline for the experimental parameters. Anl excisional biopsy of the treatment site including any remaining residual lesional tissue (excision of oral dysplastic lesions is consistent with current standards of care) will be obtained after 3 months of treatment to provide a posttreatment diagnosis. The 0 to 8 histologic scale was:0=normal with or without hyperkeratosis BEST OUTCOME, 1=atypia, 2=mild dysplasia, 3=mild-moderate dysplasia, 4=moderate dysplasia,5=moderate-severe dysplasia,6=severe dysplasia, 7=carcinoma in situ, 8=invasive oral squamous cell carcinoma (WORST OUTCOME).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Lesional Sizes</measure>
    <time_frame>pretreatment and posttreatment (3 months treatment duration)</time_frame>
    <description>The remaining oral dysplasia lesion will be inspected at each follow up appointment (every 10-14 days). Biopsies will be immediately conducted on patients with any indication of malignant transformation including indurated, rolled borders, nonhealing ulcers, etc. Accordingly, these patients will withdraw from the trial. Participants will also be monitored for any changes consistent with contact mucositis e.g. soreness and erythema at application site. Clinical photographs were taken for the patients records. Pre treatment and post treatment photographs, with a ruler in place, were used for accurate pre and post treatment size measurement. NOTE: if treatment is beneficial, lesional size will decrease which will be reflected as a negative number.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Changes in Loss of Heterozygosity Events</measure>
    <time_frame>Before and after the 3 month treatment duration</time_frame>
    <description>Laboratory experiments will be conducted to assess the effects of gel treatment on pre and post loss of heterozygosity (LOH) events at loci associated with tumor suppressor genes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Squamous Cell Carcinoma of Mouth</condition>
  <condition>Intraepithelial Neoplasia</condition>
  <arm_group>
    <arm_group_label>10% FBR containing bioadhesive gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug consisting of 10% FBR containing bioadhesive gel. Participants instructed to apply 0.5 gm of 10% FBR containing bioadhesive gel four times a day to lesional site</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Color/consistency matched placebo (no black raspberry) gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10% FBR containing bioadhesive gel</intervention_name>
    <description>0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months</description>
    <arm_group_label>10% FBR containing bioadhesive gel</arm_group_label>
    <other_name>BRB gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo gel</intervention_name>
    <description>0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months</description>
    <arm_group_label>Placebo Gel</arm_group_label>
    <other_name>BRB devoid placebo gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ages: 21 to 80

          2. Microscopically confirmed premalignant oral epithelial disease

          3. No previous history of cancer (with the exception of basal cell carcinoma of the skin)

          4. Tobacco free for at least six weeks prior to entrance in the trial and remain
             tobacco-free for the three month duration of the study

          5. Availability for necessary study follow-up evaluations (every 10 to 14 days during the
             trial)

          6. Capable of providing informed consent.

        Exclusion Criteria:

          1. Previous history of cancer (with the exception of basal cell carcinoma of the skin)

          2. Current use of tobacco products or refusal to remain tobacco-free for the three month
             duration of the study

          3. Lack of microscopically confirmed premalignant oral epithelial changes

          4. Microscopic diagnosis of oral squamous cell carcinoma

          5. Previous history of radiation therapy on same side of the head and neck region

          6. History of allergy to any kind of berry

          7. Women who are determined to be pregnant or plan to be pregnant during the trial

          8. Women who are nursing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan R Mallery, DDS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Louisville, School of Dentistry</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University, College of Dentistry</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Menzin J, Lines LM, Manning LN. The economics of squamous cell carcinoma of the head and neck. Curr Opin Otolaryngol Head Neck Surg. 2007 Apr;15(2):68-73. Review.</citation>
    <PMID>17413405</PMID>
  </reference>
  <reference>
    <citation>Lefebvre JL. Current clinical outcomes demand new treatment options for SCCHN. Ann Oncol. 2005;16 Suppl 6:vi7-vi12. Review.</citation>
    <PMID>15987995</PMID>
  </reference>
  <reference>
    <citation>Papadimitrakopoulou VA, Clayman GL, Shin DM, Myers JN, Gillenwater AM, Goepfert H, El-Naggar AK, Lewin JS, Lippman SM, Hong WK. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg. 1999 Oct;125(10):1083-9.</citation>
    <PMID>10522499</PMID>
  </reference>
  <reference>
    <citation>Rudin CM, Cohen EE, Papadimitrakopoulou VA, Silverman S Jr, Recant W, El-Naggar AK, Stenson K, Lippman SM, Hong WK, Vokes EE. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol. 2003 Dec 15;21(24):4546-52. Epub 2003 Nov 3.</citation>
    <PMID>14597742</PMID>
  </reference>
  <reference>
    <citation>Lippman SM, Lee JJ, Martin JW, El-Naggar AK, Xu X, Shin DM, Thomas M, Mao L, Fritsche HA Jr, Zhou X, Papadimitrakopoulou V, Khuri FR, Tran H, Clayman GL, Hittelman WN, Hong WK, Lotan R. Fenretinide activity in retinoid-resistant oral leukoplakia. Clin Cancer Res. 2006 May 15;12(10):3109-14.</citation>
    <PMID>16707609</PMID>
  </reference>
  <reference>
    <citation>Toma S, Benso S, Albanese E, Palumbo R, Cantoni E, Nicol√≤ G, Mangiante P. Treatment of oral leukoplakia with beta-carotene. Oncology. 1992;49(2):77-81.</citation>
    <PMID>1574255</PMID>
  </reference>
  <reference>
    <citation>Lippman SM, Batsakis JG, Toth BB, Weber RS, Lee JJ, Martin JW, Hays GL, Goepfert H, Hong WK. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med. 1993 Jan 7;328(1):15-20.</citation>
    <PMID>8416267</PMID>
  </reference>
  <reference>
    <citation>Shin DM, Mao L, Papadimitrakopoulou VM, Clayman G, El-Naggar A, Shin HJ, Lee JJ, Lee JS, Gillenwater A, Myers J, Lippman SM, Hittelman WN, Hong WK. Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression. J Natl Cancer Inst. 2000 Jan 5;92(1):69-73.</citation>
    <PMID>10620636</PMID>
  </reference>
  <reference>
    <citation>Papadimitrakopoulou VA, William WN Jr, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, Peterson DE, Feng L, Atwell A, El-Naggar AK, Nathan CO, Helman JI, Du B, Yueh B, Boyle JO. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res. 2008 Apr 1;14(7):2095-101. doi: 10.1158/1078-0432.CCR-07-4024.</citation>
    <PMID>18381950</PMID>
  </reference>
  <reference>
    <citation>William WN Jr, Lee JJ, Lippman SM, Martin JW, Chakravarti N, Tran HT, Sabichi AL, Kim ES, Feng L, Lotan R, Papadimitrakopoulou VA. High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila). 2009 Jan;2(1):22-6. doi: 10.1158/1940-6207.CAPR-08-0100.</citation>
    <PMID>19139014</PMID>
  </reference>
  <reference>
    <citation>Meyskens FL Jr. Another negative chemoprevention trial: what can we learn? Clin Cancer Res. 2008 Jan 1;14(1):2-3. doi: 10.1158/1078-0432.CCR-07-2215.</citation>
    <PMID>18172244</PMID>
  </reference>
  <reference>
    <citation>Rodrigo KA, Rawal Y, Renner RJ, Schwartz SJ, Tian Q, Larsen PE, Mallery SR. Suppression of the tumorigenic phenotype in human oral squamous cell carcinoma cells by an ethanol extract derived from freeze-dried black raspberries. Nutr Cancer. 2006;54(1):58-68.</citation>
    <PMID>16800773</PMID>
  </reference>
  <reference>
    <citation>Chen T, Rose ME, Hwang H, Nines RG, Stoner GD. Black raspberries inhibit N-nitrosomethylbenzylamine (NMBA)-induced angiogenesis in rat esophagus parallel to the suppression of COX-2 and iNOS. Carcinogenesis. 2006 Nov;27(11):2301-7. Epub 2006 Jun 15.</citation>
    <PMID>16777990</PMID>
  </reference>
  <reference>
    <citation>Chen T, Hwang H, Rose ME, Nines RG, Stoner GD. Chemopreventive properties of black raspberries in N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis: down-regulation of cyclooxygenase-2, inducible nitric oxide synthase, and c-Jun. Cancer Res. 2006 Mar 1;66(5):2853-9.</citation>
    <PMID>16510608</PMID>
  </reference>
  <reference>
    <citation>Kresty LA, Morse MA, Morgan C, Carlton PS, Lu J, Gupta A, Blackwood M, Stoner GD. Chemoprevention of esophageal tumorigenesis by dietary administration of lyophilized black raspberries. Cancer Res. 2001 Aug 15;61(16):6112-9.</citation>
    <PMID>11507061</PMID>
  </reference>
  <reference>
    <citation>Xue H, Aziz RM, Sun N, Cassady JM, Kamendulis LM, Xu Y, Stoner GD, Klaunig JE. Inhibition of cellular transformation by berry extracts. Carcinogenesis. 2001 Feb;22(2):351-6. Erratum in: Carcinogenesis 2001 May;22(5):831-3.</citation>
    <PMID>11181460</PMID>
  </reference>
  <reference>
    <citation>Huang C, Huang Y, Li J, Hu W, Aziz R, Tang MS, Sun N, Cassady J, Stoner GD. Inhibition of benzo(a)pyrene diol-epoxide-induced transactivation of activated protein 1 and nuclear factor kappaB by black raspberry extracts. Cancer Res. 2002 Dec 1;62(23):6857-63.</citation>
    <PMID>12460899</PMID>
  </reference>
  <reference>
    <citation>Huang C, Li J, Song L, Zhang D, Tong Q, Ding M, Bowman L, Aziz R, Stoner GD. Black raspberry extracts inhibit benzo(a)pyrene diol-epoxide-induced activator protein 1 activation and VEGF transcription by targeting the phosphotidylinositol 3-kinase/Akt pathway. Cancer Res. 2006 Jan 1;66(1):581-7.</citation>
    <PMID>16397275</PMID>
  </reference>
  <reference>
    <citation>Hecht SS, Huang C, Stoner GD, Li J, Kenney PM, Sturla SJ, Carmella SG. Identification of cyanidin glycosides as constituents of freeze-dried black raspberries which inhibit anti-benzo[a]pyrene-7,8-diol-9,10-epoxide induced NFkappaB and AP-1 activity. Carcinogenesis. 2006 Aug;27(8):1617-26. Epub 2006 Mar 7.</citation>
    <PMID>16522666</PMID>
  </reference>
  <reference>
    <citation>Stoner GD. Foodstuffs for preventing cancer: the preclinical and clinical development of berries. Cancer Prev Res (Phila). 2009 Mar;2(3):187-94. doi: 10.1158/1940-6207.CAPR-08-0226. Epub 2009 Mar 3.</citation>
    <PMID>19258544</PMID>
  </reference>
  <reference>
    <citation>Wang LS, Hecht SS, Carmella SG, Yu N, Larue B, Henry C, McIntyre C, Rocha C, Lechner JF, Stoner GD. Anthocyanins in black raspberries prevent esophageal tumors in rats. Cancer Prev Res (Phila). 2009 Jan;2(1):84-93. doi: 10.1158/1940-6207.CAPR-08-0155.</citation>
    <PMID>19139022</PMID>
  </reference>
  <reference>
    <citation>Shumway BS, Kresty LA, Larsen PE, Zwick JC, Lu B, Fields HW, Mumper RJ, Stoner GD, Mallery SR. Effects of a topically applied bioadhesive berry gel on loss of heterozygosity indices in premalignant oral lesions. Clin Cancer Res. 2008 Apr 15;14(8):2421-30. doi: 10.1158/1078-0432.CCR-07-4096.</citation>
    <PMID>18413833</PMID>
  </reference>
  <reference>
    <citation>Mallery SR, Zwick JC, Pei P, Tong M, Larsen PE, Shumway BS, Lu B, Fields HW, Mumper RJ, Stoner GD. Topical application of a bioadhesive black raspberry gel modulates gene expression and reduces cyclooxygenase 2 protein in human premalignant oral lesions. Cancer Res. 2008 Jun 15;68(12):4945-57. doi: 10.1158/0008-5472.CAN-08-0568.</citation>
    <PMID>18559542</PMID>
  </reference>
  <reference>
    <citation>Ugalde CM, Liu Z, Ren C, Chan KK, Rodrigo KA, Ling Y, Larsen PE, Chacon GE, Stoner GD, Mumper RJ, Fields HW, Mallery SR. Distribution of anthocyanins delivered from a bioadhesive black raspberry gel following topical intraoral application in normal healthy volunteers. Pharm Res. 2009 Apr;26(4):977-86. doi: 10.1007/s11095-008-9806-x. Epub 2009 Jan 10.</citation>
    <PMID>19137418</PMID>
  </reference>
  <reference>
    <citation>Lang K, Menzin J, Earle CC, Jacobson J, Hsu MA. The economic cost of squamous cell cancer of the head and neck: findings from linked SEER-Medicare data. Arch Otolaryngol Head Neck Surg. 2004 Nov;130(11):1269-75.</citation>
    <PMID>15545580</PMID>
  </reference>
  <reference>
    <citation>Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.</citation>
    <PMID>18287387</PMID>
  </reference>
  <reference>
    <citation>Silverman S Jr, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer. 1984 Feb 1;53(3):563-8.</citation>
    <PMID>6537892</PMID>
  </reference>
  <reference>
    <citation>Sciubba JJ. Oral leukoplakia. Crit Rev Oral Biol Med. 1995;6(2):147-60. Review.</citation>
    <PMID>7548621</PMID>
  </reference>
  <reference>
    <citation>Speight PM. Update on oral epithelial dysplasia and progression to cancer. Head Neck Pathol. 2007 Sep;1(1):61-6. doi: 10.1007/s12105-007-0014-5. Epub 2007 Nov 30.</citation>
    <PMID>20614284</PMID>
  </reference>
  <reference>
    <citation>Helzer LJ, Heitkamp KM, Shein M, Etzel RA. Pilot study of methods to measure saliva cotinine in Alaska Native women during pregnancy. Int J Circumpolar Health. 2007;66 Suppl 1:29-38.</citation>
    <PMID>18154230</PMID>
  </reference>
  <reference>
    <citation>Mao L, Lee JS, Fan YH, Ro JY, Batsakis JG, Lippman S, Hittelman W, Hong WK. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med. 1996 Jun;2(6):682-5.</citation>
    <PMID>8640560</PMID>
  </reference>
  <reference>
    <citation>Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, Edelstein D, Soslow RA, Koki AT, Woerner BM, Masferrer JL, Dannenberg AJ. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 1999 Mar 1;59(5):991-4.</citation>
    <PMID>10070952</PMID>
  </reference>
  <reference>
    <citation>Connelly ST, Macabeo-Ong M, Dekker N, Jordan RC, Schmidt BL. Increased nitric oxide levels and iNOS over-expression in oral squamous cell carcinoma. Oral Oncol. 2005 Mar;41(3):261-7.</citation>
    <PMID>15743688</PMID>
  </reference>
  <reference>
    <citation>Kawanishi S, Hiraku Y, Pinlaor S, Ma N. Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol Chem. 2006 Apr;387(4):365-72. Review.</citation>
    <PMID>16606333</PMID>
  </reference>
  <reference>
    <citation>Mann JR, Backlund MG, DuBois RN. Mechanisms of disease: Inflammatory mediators and cancer prevention. Nat Clin Pract Oncol. 2005 Apr;2(4):202-10. Review.</citation>
    <PMID>16264935</PMID>
  </reference>
  <reference>
    <citation>Joshi N, Johnson LL, Wei WQ, Abnet CC, Dong ZW, Taylor PR, Limburg PJ, Dawsey SM, Hawk ET, Qiao YL, Kirsch IR. Gene expression differences in normal esophageal mucosa associated with regression and progression of mild and moderate squamous dysplasia in a high-risk Chinese population. Cancer Res. 2006 Jul 1;66(13):6851-60.</citation>
    <PMID>16818663</PMID>
  </reference>
  <reference>
    <citation>Otrock ZK, Mahfouz RA, Makarem JA, Shamseddine AI. Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells Mol Dis. 2007 Sep-Oct;39(2):212-20. Epub 2007 Jun 6. Review.</citation>
    <PMID>17553709</PMID>
  </reference>
  <reference>
    <citation>Tong M, Lloyd B, Pei P, Mallery SR. Human head and neck squamous cell carcinoma cells are both targets and effectors for the angiogenic cytokine, VEGF. J Cell Biochem. 2008 Dec 1;105(5):1202-10. doi: 10.1002/jcb.21920.</citation>
    <PMID>18802921</PMID>
  </reference>
  <reference>
    <citation>Kannan R, Bijur GN, Mallery SR, Beck FM, Sabourin CL, Jewell SD, Schuller DE, Stoner GD. Transforming growth factor-alpha overexpression in proliferative verrucous leukoplakia and oral squamous cell carcinoma: an immunohistochemical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Jul;82(1):69-74.</citation>
    <PMID>8843456</PMID>
  </reference>
  <reference>
    <citation>Wang LS, Stoner GD. Anthocyanins and their role in cancer prevention. Cancer Lett. 2008 Oct 8;269(2):281-90. doi: 10.1016/j.canlet.2008.05.020. Epub 2008 Jun 20. Review.</citation>
    <PMID>18571839</PMID>
  </reference>
  <results_reference>
    <citation>Mallery SR, Tong M, Shumway BS, Curran AE, Larsen PE, Ness GM, Kennedy KS, Blakey GH, Kushner GM, Vickers AM, Han B, Pei P, Stoner GD. Topical application of a mucoadhesive freeze-dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo-controlled clinical trial. Clin Cancer Res. 2014 Apr 1;20(7):1910-24. doi: 10.1158/1078-0432.CCR-13-3159. Epub 2014 Jan 31.</citation>
    <PMID>24486592</PMID>
  </results_reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2010</study_first_submitted>
  <study_first_submitted_qc>August 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2010</study_first_posted>
  <results_first_submitted>April 29, 2015</results_first_submitted>
  <results_first_submitted_qc>August 12, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 14, 2015</results_first_posted>
  <last_update_submitted>August 12, 2015</last_update_submitted>
  <last_update_submitted_qc>August 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Susan Mallery DDS, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>FBR, OSCC, chemoprevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Mouth Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>41 patients were enrolled in this protocol. 1 patient could not keep the appointments and was referred to his private oral surgeon.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>10% FBR Gel</title>
          <description>Active 10% FBR containing bioadhesive gel
Bioadhesive 10% freeze-dried black raspberry gel: 0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months</description>
        </group>
        <group group_id="P2">
          <title>Placebo Gel</title>
          <description>Color/consistency matched placebo (no black raspberry) gel
Color/consistency matched placebo gel: 0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>could not keep recall appointments</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>10% FBR Gel</title>
          <description>Active 10% FBR containing bioadhesive gel
Bioadhesive 10% freeze-dried black raspberry gel: 0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months</description>
        </group>
        <group group_id="B2">
          <title>Placebo Gel</title>
          <description>Color/consistency matched placebo (no black raspberry) gel
Color/consistency matched placebo gel: 0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>The patients were randomly assigned by computer generated numbers to either the BRB or the placebo gel groups.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.2" spread="1.8"/>
                    <measurement group_id="B2" value="57.7" spread="2.9"/>
                    <measurement group_id="B3" value="59.9" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Light Microscopic Histologically Scored Diagnoses Pretreatment to Post Treatment</title>
        <description>A hemisection of lesional tissue will be conducted before the 3 month treatment to establish a diagnosis and provide a pretreatment baseline for the experimental parameters. Anl excisional biopsy of the treatment site including any remaining residual lesional tissue (excision of oral dysplastic lesions is consistent with current standards of care) will be obtained after 3 months of treatment to provide a posttreatment diagnosis. The 0 to 8 histologic scale was:0=normal with or without hyperkeratosis BEST OUTCOME, 1=atypia, 2=mild dysplasia, 3=mild-moderate dysplasia, 4=moderate dysplasia,5=moderate-severe dysplasia,6=severe dysplasia, 7=carcinoma in situ, 8=invasive oral squamous cell carcinoma (WORST OUTCOME).</description>
        <time_frame>Before and after the 3 month treatment.</time_frame>
        <population>The population evaluated were as previously described i.e. 22 participants in the BRB gel cohort and 18 participants in the placebo gel cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>10% FBR Gel</title>
            <description>Active 10% FBR containing bioadhesive gel
Bioadhesive 10% freeze-dried black raspberry gel: 0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo Gel</title>
            <description>Color/consistency matched placebo (no black raspberry) gel
Color/consistency matched placebo gel: 0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Light Microscopic Histologically Scored Diagnoses Pretreatment to Post Treatment</title>
          <description>A hemisection of lesional tissue will be conducted before the 3 month treatment to establish a diagnosis and provide a pretreatment baseline for the experimental parameters. Anl excisional biopsy of the treatment site including any remaining residual lesional tissue (excision of oral dysplastic lesions is consistent with current standards of care) will be obtained after 3 months of treatment to provide a posttreatment diagnosis. The 0 to 8 histologic scale was:0=normal with or without hyperkeratosis BEST OUTCOME, 1=atypia, 2=mild dysplasia, 3=mild-moderate dysplasia, 4=moderate dysplasia,5=moderate-severe dysplasia,6=severe dysplasia, 7=carcinoma in situ, 8=invasive oral squamous cell carcinoma (WORST OUTCOME).</description>
          <population>The population evaluated were as previously described i.e. 22 participants in the BRB gel cohort and 18 participants in the placebo gel cohort.</population>
          <units>unit on histologic grade scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pretreatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36" spread="0.35"/>
                    <measurement group_id="O2" value="2.83" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posttreatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.21"/>
                    <measurement group_id="O2" value="2.58" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Wilcoxon matched-pairs signed rank test (intrapatient pre versus post treatment scores)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.048</p_value>
            <p_value_desc>Statistical analyses reflect percent change intrapatient pre versus post histologic grade scores</p_value_desc>
            <method>Wilcoxon matched-pairs signed rank test</method>
            <method_desc>We used a 2-tailed Mann Whitney U test to evaluate these data.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Wilcoxon matched-pairs signed rank test (pre versus post treatment scores)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.50</p_value>
            <p_value_desc>Statistical analyses reflect percent change pre versus post histologic grade scores</p_value_desc>
            <method>Wilcoxon matched-pairs signed rank test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Lesional Sizes</title>
        <description>The remaining oral dysplasia lesion will be inspected at each follow up appointment (every 10-14 days). Biopsies will be immediately conducted on patients with any indication of malignant transformation including indurated, rolled borders, nonhealing ulcers, etc. Accordingly, these patients will withdraw from the trial. Participants will also be monitored for any changes consistent with contact mucositis e.g. soreness and erythema at application site. Clinical photographs were taken for the patients records. Pre treatment and post treatment photographs, with a ruler in place, were used for accurate pre and post treatment size measurement. NOTE: if treatment is beneficial, lesional size will decrease which will be reflected as a negative number.</description>
        <time_frame>pretreatment and posttreatment (3 months treatment duration)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10% FBR Gel</title>
            <description>Active 10% FBR containing bioadhesive gel
Bioadhesive 10% freeze-dried black raspberry gel: 0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Gel</title>
            <description>Color/consistency matched placebo (no black raspberry) gel
Color/consistency matched placebo gel: 0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Lesional Sizes</title>
          <description>The remaining oral dysplasia lesion will be inspected at each follow up appointment (every 10-14 days). Biopsies will be immediately conducted on patients with any indication of malignant transformation including indurated, rolled borders, nonhealing ulcers, etc. Accordingly, these patients will withdraw from the trial. Participants will also be monitored for any changes consistent with contact mucositis e.g. soreness and erythema at application site. Clinical photographs were taken for the patients records. Pre treatment and post treatment photographs, with a ruler in place, were used for accurate pre and post treatment size measurement. NOTE: if treatment is beneficial, lesional size will decrease which will be reflected as a negative number.</description>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.12" spread="5.81"/>
                    <measurement group_id="O2" value="18.12" spread="4.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.002</p_value>
            <method>Wilcoxon matched-pairs signed rank test</method>
            <method_desc>specifically, we used the Wilcoxon matched-pairs signed rank test.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.036</p_value>
            <method>Wilcoxon matched-pairs signed rank test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Changes in Loss of Heterozygosity Events</title>
        <description>Laboratory experiments will be conducted to assess the effects of gel treatment on pre and post loss of heterozygosity (LOH) events at loci associated with tumor suppressor genes.</description>
        <time_frame>Before and after the 3 month treatment duration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10% FBR Gel</title>
            <description>Active 10% FBR containing bioadhesive gel
Bioadhesive 10% freeze-dried black raspberry gel: 0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo Gel</title>
            <description>Color/consistency matched placebo (no black raspberry) gel
Color/consistency matched placebo gel: 0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Changes in Loss of Heterozygosity Events</title>
          <description>Laboratory experiments will be conducted to assess the effects of gel treatment on pre and post loss of heterozygosity (LOH) events at loci associated with tumor suppressor genes.</description>
          <units>LOH events</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.02"/>
                    <measurement group_id="O2" value="0.4" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>2-tailed unpaired t test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>two-tailed unpaired t test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>10% FBR Gel</title>
          <description>Active 10% FBR containing bioadhesive gel
Bioadhesive 10% freeze-dried black raspberry gel: 0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
No adverse events</description>
        </group>
        <group group_id="E2">
          <title>Placebo Gel</title>
          <description>Color/consistency matched placebo (no black raspberry) gel
Color/consistency matched placebo gel: 0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
No adverse events</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>While we initially planned to include microvascular densities and COX-2 analyses, there were insufficient tissue samples to collect these data. Therefore as we do not have these data we can not report them.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Susan R, Mallery DDS, PhD</name_or_title>
      <organization>The Ohio State University</organization>
      <phone>614 292-5892</phone>
      <email>mallery.1@osu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

